Abstract
Background: The steady increase in microbial resistance is a global health problem as a result of uncontrolled use of antimicrobial drugs, In order to overcome the challenge, there is a continuous need to search for new antimicrobials by either investigate novel compounds or repurposing drugs i.e. identifying new clinical use for existing approved agent thus saving time and cost required to develop a new antimicrobial therapy. Aim: This study aimed to assess the in vitro antimycotic activity of different concentrations of rosuvastatin against 4 different fungi isolated from patients with malignancies 1 mold of genus Aspergillus, of 3 spices (A. flavus, A.niger, and A. fumigatus) and 3 yeast of genus Candida of2species (C. albicans , and C. glabrata), one genus and species from each Saccharomyces cerevisiae , and Rhodotoryoa rubra by disc diffusion method. Materials and Methods: Sputum was taken from 30 patients with malignant disease, different micro and macroscopical tests were used to identified the 14 isolated fungi from them 1 genus from mold of Aspergillus, and 3 genus from yeast, from genus Aspergillus 3 species recognized as tailed, A. flavus, A. niger, and A.fumigatus. On the other handfrom yeast of genus Candida, C.albicans and C.glabrata, whereas from genus Saccharomyces, and Rhodotoula, Saccharomyces cerevisiae and Rhodotoula rubra were recognized. Results: Antimycotic susceptibility test exhibited zone of inhibition against yeast ranged from (30-20), (30-15), (30-15), and (25-15) against C.albicans, C.glabrata Saccharomyces cerevisiae and Rhodotoula rubra respectively, while mold show zone of inhibition ranged from (25-10), (10-0), and (30-10) against A.flavus, A.niger, and A.fumigatus respectively, although rosuvastatin show an antifungal activity only at dose 0.6 mg/ml against A. niger. Conclusion: Rosuvastatin has antifungal activity apart of its pleiotropic activity of statins.
